{
  "rejected_claims": [
    {
      "filename": "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md",
      "issues": [
        "missing_attribution_extractor"
      ]
    },
    {
      "filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md",
      "issues": [
        "missing_attribution_extractor"
      ]
    }
  ],
  "validation_stats": {
    "total": 2,
    "kept": 0,
    "fixed": 2,
    "rejected": 2,
    "fixes_applied": [
      "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:set_created:2026-03-16",
      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md:set_created:2026-03-16"
    ],
    "rejections": [
      "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:missing_attribution_extractor",
      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md:missing_attribution_extractor"
    ]
  },
  "model": "anthropic/claude-sonnet-4.5",
  "date": "2026-03-16"
}